Skip to content

Compounds · Heart, blood & kidney · Mitochondrial function enhancement in cardiovascular disease

SS-31 (Elamipretide / Bendavia)

Full protocol

Elamipretide, Bendavia, MTP-131, Szeto-Schiller-31

Known as Elamipretide, this tetrapeptide binds cardiolipin on the inner mitochondrial membrane to stabilize mitochondrial structure and support ATP production. It recently gained FDA accelerated approval, as Forzinity, for Barth syndrome, a rare mitochondrial genetic disorder.

5–10 mg, 2–3× weekly

Research score 80/100. Reference only, not a prescription.

  • Cardiovascular Health
  • Mitochondrial Function
  • Antioxidant
  • Cardioprotection
  • Kidney Protection
US status
Investigational
Approval
Phase 3 Clinical Trial
Evidence
FDA Accelerated Approval (Forzinity) for Barth Syndrome (2025). Phase 3 trials for PMM and dry AMD.
Research score
80 / 100
Indication
Heart Failure
Origin
USA
Source category
Heart & Cardiovascular
Status group
Investigational

Mechanism

Its alternating aromatic-cationic sequence lets it concentrate heavily in mitochondria, where cardiolipin binding blocks damaging cytochrome c peroxidase activity and stabilizes cristae structure, improving electron transport chain efficiency, lowering reactive oxygen species, and preserving membrane potential and fusion/fission balance, especially during ischemia-reperfusion stress.

Safety file

Injection-site reactions are common, around 80% of users; otherwise generally well tolerated.

  • Injection site reactions
  • Headache
  • Nausea
  • Dizziness

Reconstitution

Concentration by vial size and water volume
Vial2 mL water3 mL water
50 mg25 mg/mL16.67 mg/mL

SS-31 can cause a welt at the injection site. Bac water containing 0.9% sodium chloride reduces that reaction for some people. Plain bac water also works.

  1. Use bacteriostatic water as the diluent.
  2. Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
  3. Swirl gently to mix, then leave it to dissolve. Do not shake.
  4. Give it a few minutes. The finished solution should be clear and colourless.

Full mixing method

Protocol

Route: Subcutaneous

Standard protocol (subcutaneous)

  • 5 mg to 10 mg per dose
  • Two to three times weekly is the common frequency, though some run it daily
  • At a 3 mL fill on the 50 mg vial (16.7 mg/mL), 5 mg is a 0.3 mL draw (30 units)

Dosing detail

  • Common dose is 5 mg to 10 mg per injection, most often 2 to 3 times weekly (some dose daily).
  • A mitochondria-targeted peptide (elamipretide), studied for energy, recovery and ageing. The pharmaceutical version was FDA-approved in 2025 (Forzinity) for a rare mitochondrial disease, at higher clinical doses than these.
  • Effects are internal and gradual rather than something you see day to day.

Duration

  • Run in 4 to 6 week blocks. It is used for cellular energy, recovery and ageing rather than a quick visible effect.

Notes

  • Targets the mitochondria; studied for cellular energy and recovery.
  • Inject subcutaneously and rotate sites.
  • A small welt can occur; saline bac water helps.

Storage and handling

  • Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
  • Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
  • Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
  • If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.

Storage rules and when to discard